FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series B / Biotech startups that raised Series B in China

Biotech startups that raised Series B in China

Updated 16 Nov 2026

Reset
Biotech startups that raised Series B in China
One-time CSV
  • 301 funded companies, 222 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-b~china-500a.csv301 rows × 18 columns
CompanyCityLast roundAmountDate
Huasaiboman Medical Cell BiologyQingdao ShiSeries B$30.0M2026-11-09
EnjosimShanghaiSeries B$30.1M2026-11-02
Bluesail SurgicalShanghaiSeries B$104.5M2026-09-23
MedefaZhuhaiSeries B$14.9M2026-09-02
Yuce BiotechnologySuzhouSeries B$7.4M2026-08-31
Hongxin BiologyShenzhenSeries B$14.0M2026-08-13
Layerwave BioDaxingSeries B$13.8M2026-07-28
MindRank AIShanghaiSeries B$52.0M2026-07-08

8 rows of the CSV in 5 of its 18 columns.

301
Startups
$9.1B
Total raised
54
Funded in the last 12 months
$1.3B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

29 of 301
29 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
Medefa Medefa uses synthetic biology to mass-produce novel PHA biomaterials. Biotech Zhuhai Series B $14.9M 2026-09-02 $16.3M Motianshi Touzi, Taiping Innovation 11 to 50 2019
Yuce Biotechnology Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. Biotech Suzhou Series B $7.4M 2026-08-31 $22.4M Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 101 to 250 2019
Hongxin Biology Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. Biotech Shenzhen Series B $14.0M 2026-08-13 $14.0M Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group 11 to 50 2021
Layerwave Bio Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. Biotech Daxing Series B $13.8M 2026-07-28 $13.8M IDG Capital, Addor Capital, Hotung Venture Capital 51 to 100 2020
MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
ThunderBio Innovation ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. Biotech Jiaxing Series B $17.7M 2026-06-15 $34.6M Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi 11 to 50 2018
HemaCell HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. Biotech Suzhou Series B $14.8M 2026-06-02 $62.0M Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation 1 to 10 2021
Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
Novamab Novamab researches and develops new nanobodies. Biotech Shanghai Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
Findcure Findcure develops anti-cancer medications through drug discovery and development. Biotech Daxing Series B $14.5M 2026-02-14 $14.5M Hecheng Capital, Renxi Fund, Yishang Huicheng Investments 11 to 50 2019
Transcend Vivoscope Transcend Vivoscope is a biotechnology company that offers advanced microscopy imaging products and solutions. Biotech Haidian Series B $14.5M 2026-02-10 $14.5M China Capital Management, Zefu Innovation, Guangzhou Tongxin Science and Technology Innovation Fund 11 to 50 2016
Alioth Alioth develops and applies technical products for pharmaceutical process technology. Biotech Shanghai Series B $14.4M 2026-01-15 $54.7M Matrix Partners China, Legend Capital 51 to 100 2021
Anlong Bio Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. Biotech Beijing Series B $14.3M 2026-01-07 $14.3M TaiKun Fund 51 to 100 2019
D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
Rigen Biotech Rigen Biotech provides molecular diagnosis of thyroid tumors. Biotech Minhang Series B $14.1M 2025-11-28 $29.8M BioTrack Capital, Boyuan Capital, Guotai Junan Innovation Investment +1 101 to 250 2017
Alpha Biopharma Alpha Biopharma is a clinical-stage biopharmaceutical company. Biotech Huangpu Series B $23.9M 2024-06-22 Qiming Venture Partners, TF Capital, LYZZ Capital 51 to 100 2017
CureGenetics CureGenetics develops medicines and molecular diagnostics for cancers and genetic diseases. Biotech Suzhou Series B $9.0M 2024-03-28 Qiming Venture Partners, Oriza Holdings, Qingsong Fund +1 51 to 100 2016
Hengyu Biotechnology Hengyu Biotechnology provides biosafety testing and process validation through a CXO platform. Biotech Jiaxing Series B $27.8M 2024-03-11 CMB International Capital Corporation, GP Capital, Haibang Capital +2 101 to 250 2020
Precedo Biomedical Precedo Biomedical specializes in industrial safety and national strategic biosafety. Biotech Hefei Series B $13.8M 2023-11-14 Sunland Fund 101 to 250 2015
Raisecare Raisecare conducts life science research, sells life science goods, and develops in vitro diagnostic tools. Biotech Qingdao Shi Series B $13.7M 2023-11-03 $13.7M CICC Capital, CITIC Medical Fund, Chongqing Yinuo 251 to 500 2016
Onechip Bioelectronics Onechip Bioelectronics develops biosensor chips and nanomaterials. Biotech Zhangjiagang Series B $13.7M 2023-09-28 Matrix Partners China, Qiming Venture Partners, Xiamen C&D Emerging Industry Equity Investment +1 11 to 50 2014
Chuangjian Medical Chuangjian Medical Technology develops, sells, and researches novel protein and nucleic acid-based medicines. Biotech Changzhou Series B $27.5M 2023-09-16 $57.2M CDH Investments, L Catterton, CDF-Capital +1 101 to 250 2015
Qihan Biotech Qihan Biotech develops gene-editing technology for organ transplantation. Biotech Hangzhou Series B $16.0M 2023-09-15 $116.3M Matrix Partners China, Northern Light Venture Capital, CMB International Capital Corporation +1 101 to 250 2017
StoneWise StoneWise builds an intelligent drug discovery platform for pharmaceutical research. Artificial intelligence Haidian Series B $100.0M 2021-04-12 Legend Capital, Luminous Ventures (former Lightspeed China Partners), Hillhouse Ventures +1 51 to 100 2018
Crabyter Crabyter develops a platform for managing clinical scientific research data. Biotech Putuo Series B $2.9M 2016-12-07 $6.5M PreAngel, Kaitai Capital, Prox Ventures +1 101 to 250 2013

Table 1. Biotech startups that raised Series B in China: the 29 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 301.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
2 Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
3 Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
4 MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
5 CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
6 Novamab Novamab researches and develops new nanobodies. Biotech Shanghai Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
7 Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
8 Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
9 ThunderBio Innovation ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. Biotech Jiaxing Series B $17.7M 2026-06-15 $34.6M Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi 11 to 50 2018
10 Medefa Medefa uses synthetic biology to mass-produce novel PHA biomaterials. Biotech Zhuhai Series B $14.9M 2026-09-02 $16.3M Motianshi Touzi, Taiping Innovation 11 to 50 2019

Table 2. Biotech startups that raised Series B in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 7 2% 2 Novamab, CSR Biotech
2 CMB International Capital Corporation Investment bank Central, Hong Kong 5 2% 1 HemaCell
3 Matrix Partners China Venture capital firm Beijing, China 5 2% 2 Alioth, D3 Bio
4 BioTrack Capital Venture capital firm Shanghai, China 4 1% 2 Yuce Biotechnology, Rigen Biotech
5 Northern Light Venture Capital Venture capital firm Beijing, China 4 1% 1 HemaCell
6 Legend Capital Venture capital firm Beijing, China 4 1% 1 Alioth
7 Huagai Capital Private equity firm Beijing, China 3 1% 2 Bluesail Surgical, MindRank AI
8 Addor Capital Venture capital firm Nanjing, China 3 1% 1 Layerwave Bio
9 IDG Capital Private equity firm Beijing, China 3 1% 1 Layerwave Bio
10 GL Ventures LLC Venture capital firm Beijing, China 3 1% 1 Etern
11 Gaorong Capital Venture capital firm Wangjing, China 3 1% 1 Bivision
12 Lilly Asia Ventures Venture capital firm Shanghai, China 3 1%
13 CICC Capital Private equity firm Beijing, China 3 1%
14 Hillhouse Ventures Venture capital firm Singapore 3 1%
15 Luminous Ventures (former Lightspeed China Partners) Venture capital firm Shanghai, China 2 1% 1 Enjosim

Table 3. Biotech startups that raised Series B in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 261 87% $7.9B
Software 12 4% $560.2M
Artificial intelligence 9 3% $489.2M
Hardware 6 2% $74.9M
Energy 2 1% $816.8M
Fintech 1 0%

Table 4. Biotech startups that raised Series B in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 301 100% $14.9M

Table 5. Biotech startups that raised Series B in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 53 18%
Beijing 31 10%
Suzhou 28 9%
Hangzhou 23 8%
Shenzhen 18 6%
Guangzhou 11 4%
Nanjing 11 4%
Changping 8 3%
Chengdu 8 3%
Haidian 7 2%
Minhang 6 2%
Daxing 5 2%

Table 6. Biotech startups that raised Series B in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 4 7% $75.0M
October 2026 1 2% $10.5M
September 2026 6 11% $221.7M
August 2026 2 4% $21.5M
July 2026 4 7% $65.8M
June 2026 3 6% $32.5M
May 2026 4 7% $114.8M
April 2026 4 7% $75.5M
March 2026 4 7% $230.9M
February 2026 5 9% $86.7M
January 2026 8 15% $86.5M
December 2025 7 13% $216.2M
November 2025 2 4% $14.1M

Table 7. Biotech startups that raised Series B in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 45 15% $1.0B
2025 38 13% $627.4M
2024 25 8% $330.1M
2023 45 15% $806.4M
2022 40 13% $1.9B
2021 31 10% $1.6B

Table 8. Biotech startups that raised Series B in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 48 16%
2015 to 2019 136 45%
2010 to 2014 68 23%
Before 2010 48 16%

Table 9. Biotech startups that raised Series B in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 17 6%
11 to 50 84 31%
51 to 100 65 24%
101 to 250 64 24%
251 to 500 21 8%
501 to 1,000 13 5%
1,001 to 5,000 7 3%

Table 10. Biotech startups that raised Series B in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in China whose last round is Series B are on the list?
301, in the file dated 16 November 2026. 54 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 301 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series B in China: 301 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in China

Other sectors that raised Series B in China

Cite: FundingWatcher, 301 biotech companies in China whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-b/china-500a/